998 related articles for article (PubMed ID: 19538111)
1. The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks.
Handley L; Buller RM; Frey SE; Bellone C; Parker S
Expert Rev Vaccines; 2009 Jul; 8(7):841-50. PubMed ID: 19538111
[TBL] [Abstract][Full Text] [Related]
2. Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3.
Osborne JD; Da Silva M; Frace AM; Sammons SA; Olsen-Rasmussen M; Upton C; Buller RM; Chen N; Feng Z; Roper RL; Liu J; Pougatcheva S; Chen W; Wohlhueter RM; Esposito JJ
Vaccine; 2007 Dec; 25(52):8807-32. PubMed ID: 18037545
[TBL] [Abstract][Full Text] [Related]
3. New generation smallpox vaccines: a review of preclinical and clinical data.
Artenstein AW
Rev Med Virol; 2008; 18(4):217-31. PubMed ID: 18283712
[TBL] [Abstract][Full Text] [Related]
4. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults.
Artenstein AW; Johnson C; Marbury TC; Morrison D; Blum PS; Kemp T; Nichols R; Balser JP; Currie M; Monath TP
Vaccine; 2005 May; 23(25):3301-9. PubMed ID: 15837236
[TBL] [Abstract][Full Text] [Related]
5. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.
Nalca A; Zumbrun EE
Drug Des Devel Ther; 2010 May; 4():71-9. PubMed ID: 20531961
[TBL] [Abstract][Full Text] [Related]
6. An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies.
Wiser I; Balicer RD; Cohen D
Vaccine; 2007 Jan; 25(6):976-84. PubMed ID: 17074424
[TBL] [Abstract][Full Text] [Related]
7. Smallpox vaccination and bioterrorism with pox viruses.
Mayr A
Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):423-30. PubMed ID: 12818626
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults.
Frey SE; Newman FK; Kennedy JS; Ennis F; Abate G; Hoft DF; Monath TP
Vaccine; 2009 Mar; 27(10):1637-44. PubMed ID: 19071184
[TBL] [Abstract][Full Text] [Related]
9. Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.
Meseda CA; Weir JP
Future Microbiol; 2010 Sep; 5(9):1367-82. PubMed ID: 20860482
[TBL] [Abstract][Full Text] [Related]
10. [Development of a numerically additive combined vaccine against tetanus and smallpox].
Mayr A; Baljer G; Wagner C; Sailer J
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Apr; 259(2):206-18. PubMed ID: 2990123
[TBL] [Abstract][Full Text] [Related]
11. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine.
Weltzin R; Liu J; Pugachev KV; Myers GA; Coughlin B; Blum PS; Nichols R; Johnson C; Cruz J; Kennedy JS; Ennis FA; Monath TP
Nat Med; 2003 Sep; 9(9):1125-30. PubMed ID: 12925845
[TBL] [Abstract][Full Text] [Related]
12. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense.
Monath TP; Caldwell JR; Mundt W; Fusco J; Johnson CS; Buller M; Liu J; Gardner B; Downing G; Blum PS; Kemp T; Nichols R; Weltzin R
Int J Infect Dis; 2004 Oct; 8 Suppl 2():S31-44. PubMed ID: 15491873
[TBL] [Abstract][Full Text] [Related]
13. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
McCurdy LH; Larkin BD; Martin JE; Graham BS
Clin Infect Dis; 2004 Jun; 38(12):1749-53. PubMed ID: 15227622
[TBL] [Abstract][Full Text] [Related]
14. Mouse neurotoxicity test for vaccinia-based smallpox vaccines.
Li Z; Rubin SA; Taffs RE; Merchlinsky M; Ye Z; Carbone KM
Vaccine; 2004 Mar; 22(11-12):1486-93. PubMed ID: 15063573
[TBL] [Abstract][Full Text] [Related]
15. Interferon α/β Decoy Receptor Encoded by a Variant in the Dryvax Smallpox Vaccine Contributes to Virulence and Correlates with Severe Vaccine Side Effects.
Liu R; Americo JL; Earl PL; Villani J; Cotter CA; Moss B
mBio; 2022 Feb; 13(1):e0010222. PubMed ID: 35189701
[TBL] [Abstract][Full Text] [Related]
16. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.
Empig C; Kenner JR; Perret-Gentil M; Youree BE; Bell E; Chen A; Gurwith M; Higgins K; Lock M; Rice AD; Schriewer J; Sinangil F; White E; Buller RM; Dermody TS; Isaacs SN; Moyer RW
Vaccine; 2006 Apr; 24(17):3686-94. PubMed ID: 16430997
[TBL] [Abstract][Full Text] [Related]
17. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
[TBL] [Abstract][Full Text] [Related]
18. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine.
Greenberg RN; Kennedy JS
Expert Opin Investig Drugs; 2008 Apr; 17(4):555-64. PubMed ID: 18363519
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
[TBL] [Abstract][Full Text] [Related]
20. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection.
Stittelaar KJ; Neyts J; Naesens L; van Amerongen G; van Lavieren RF; Holý A; De Clercq E; Niesters HG; Fries E; Maas C; Mulder PG; van der Zeijst BA; Osterhaus AD
Nature; 2006 Feb; 439(7077):745-8. PubMed ID: 16341204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
